Visiongain has launched a new report Pharmaceutical Flexible Manufacturing Market Report 2021-2031: Forecasts by Type (Modular Manufacturing, Data-Driven Manufacturing, Others), End-user (Pharma Companies, CMOs) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Flexible Manufacturing Companies AND COVID-19 Recovery Scenarios.

Global Pharmaceutical Flexible Manufacturing Market Outlook
The Global Pharmaceutical Flexible Manufacturing Market was valued at US$xx billion in 2020. The global market is expected to witness a CAGR of xx% from 2021 to 2026 and is expected to reach US$xx billion in 2026 from its previous value of US$xx billion in 2021. Visiongain further anticipates that the region will reach US$xx billion in 2031 while growing at a CAGR of xx% from 2021 to 2031.

Changing Pharmaceutical Business Dynamics Demanding Flexibility in Manufacturing
The pharmaceutical industry is changing, and as a result, firms are facing new challenges that need them to rethink their supply chains and manufacturing processes. Huge R&D and production costs, as well as onerous constraints, restricted operational efficiency, high inventories, and long cycle times, have long been associated with the industry, particularly in biotechnology. Despite these difficulties, the industry has maintained strong profit margins until recently.

This is no longer the case since a plethora of variables is playing havoc on profit margins, including greater government regulation, counterfeiting, and generic competition, as well as shorter patent protection terms and scientific-technical breakthroughs. In today's changing economic climate, integrated planning and scheduling solutions are crucial for developing the manufacturing flexibility that businesses require to remain competitive.

Growing Acceptance of Single Use Systems Across Biopharmaceuticals Sector
In particular, the introduction & adaption of single use systems (SUS) for the biopharmaceutical sector has been a crucial facilitator in addressing the need for more flexibility. SUS has proved to be versatile and scalable, and its popularity is growing as it is adopted in new industries. SUS, like any new technology, requires expertise and solid advice on whether to use it and when to continue with traditional stainless steel solutions. It is becoming more widely employed in downstream operations, from upstream bioreactors through harvesting solutions to formulation and packing of biopharmaceutical medicinal products.

New Solutions to Provide Necessary Agility & Flexibility to the Worldwide Pharmaceutical Sector
Pharmaceutical facility planning needs new solutions to deliver the agility and flexibility required by the new pharma reality. One example is intelligent automation. Modern pharmaceutical manufacturing is heavily reliant on well-controlled computer systems, & much of the automated infrastructure is becoming obsolete, unable to meet future economic and regulatory demands. These are obviously crucial in the larger context of achieving high flexibility and intelligent integration, but they necessitate careful preparation in collaboration with experts who are familiar with commercially available solutions, their benefits, and potential hazards.

Looking ahead ten years, it's difficult to picture the pharmaceutical industry not capitalising on technological advancements in the robot sector. As compared to most other businesses, the pharmaceutical industry lags significantly behind in the usage of robot technology. Despite the reality that there are a rising number of industrial robots ready to be utilized in the highly regulated pharmaceutical industry, the technology's recognition is still lacking. Flexible solutions for aseptic processing, high-potency substance handling, complex assembly processes, and other procedures necessitate robotics and provide significant benefits that only a few organisations have attained to date. It's also worth noting that people are the primary cause of contamination of pharmaceutical items with undesired compounds.

Batch failures due to human error and contamination will be reduced if the number of individuals directly participating in the production processes is reduced. Another advantage is the elimination of the need for costly clean room facilities and all of the time-consuming and costly gowning processes. Overall system integration is progressing to new heights, which is a key component of flexible production solutions in the new pharma world. These technologies are still so new that many companies regard them as a lot of hype, yet the potential is there. The pharmaceutical business, as is often the case, will be a late adopter, but it will catch up over the forecast period.

COVID-19 Impact on Pharmaceutical Manufacturing Sector
Pharmaceutical firms are responding to the quick difficulties presented by supply chain disruptions & the need to adjust business procedures in these critical times. If the present COVID-19 pandemic continues for a long time, it may have an influence on the availability of active materials and chemicals (mostly from China), as well as pharmaceutical import and export. There's also the possibility of short & long-term negative effects on pharmaceutical production and research & development activities, as well as delays on projects that aren't tied to the core supply chain management processes. Pharma businesses must respond, recover, and survive while the entire impact of the worldwide epidemic is yet unknown.

Lower costs have been a major factor in the relocation of a large portion of manufacturing capacity to China and India in the last ten years or more. As a result, there has been significant growth in manufacturing volumes in these nations, and about 40% of registered API sites are in India or China, according to FDA statistics from 2019. Manufacturing shifts to Asia have had a direct influence on supply chain reliability, resulting in medicine shortages.

Key Questions Answered by this Report:
• What is the current size of the overall global pharmaceutical flexible manufacturing market? How much will this market be worth from 2021 to 2031?
• What are the main drivers and restraints that will shape the overall pharmaceutical flexible manufacturing market over the next ten years?
• What are the main segments within the overall pharmaceutical flexible manufacturing market?
• How much will each of these segments be worth for the period 2021 to 2031?
• How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the world pharmaceutical flexible manufacturing?
• What is their current status and how will they develop over the next ten years?
• What are their revenue potentials to 2031?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are the driving and restraining factors that will affect the world pharmaceutical flexible manufacturing market between 2021 and 2031?
• What are the main trends that will affect the world pharmaceutical flexible manufacturing market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• How will the global pharmaceutical flexible manufacturing market evolve over the forecasted period, 2021 to 2031?
• What will be the main commercial drivers for the market from 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving the highest revenues and fastest growth?
• How will that industry evolve between 2021 and 2031, especially in R&D?

Discover sales predictions for the global pharmaceutical flexible manufacturing market and submarkets
Along with revenue prediction for the overall world market, there are 2 segmentations of the pharmaceutical flexible manufacturing market, with forecasts for 3 Types, 2 End-Users each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

Who are the major players analyzed in the market?
• Avon Modular Construction
• Boehringer Ingelheim International GmbH
• Continuous Pharmaceuticals
• Cytiva
• Danaher
• Entegris
• Environmental Systems Corporation
• Eppendorf AG
• Exyte
• G-CON Manufacturing
• Germfree Laboratories
• IPM Technologies
• KeyPlants
• Lonza
• Merck KGaA
• ModuleCo Ltd.
• Modwave
• NextPharma Technologies
• NNE
• PBS Biotech, Inc.
• Pharmadule Morimatsu
• Pfizer
• Rentschler Biopharma SE
• Sartorius AG
• Solix Technologies, Inc.
• Thermo Fisher Scientific Inc.
• Zeton

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.